Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.011
Sell
RSI(14)
39.674
Neutral
STOCH(KDJ)(9,3,3)
49.858
Sell
ATR(14)
0.317
Low Volatility
CCI(14)
-33.806
Neutral
Williams %R
66.383
Sell
TRIX(12,20)
-0.522
Sell
StochRSI(14)
0.000
Oversold
Search
Evolus Inc
EOLSAdd to Watchlist
5.840USD
-0.170-2.83%
Close 07-31 16:00（ET）Quotes delayed by 15 min
384.59MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.83%
5 Days
-2.34%
1 Month
-15.36%
6 Months
+18.94%
Year to Date
-12.18%
1 Year
-36.17%
Key Figures
6.010Open
6.010High
608.88KVolume
LossP/E TTM
23.63P/E Dynamic
--Dividend TTM
0.92%Turnover Ratio
6.010Prev. Close
5.720Low
2.41MTurnover
LossP/E Static
-13.36P/B
0.00%Div Yield TTM
-20.01%ROA
10.62052wk High
0.98Volume Ratio
-50.42MNet Profit
65.84MShares
-0.6682EPS TTM
1.34Beta
-18729.61%ROE
3.86052wk Low
4.82%Amplitude
64.27%Gross Margin
384.59MMarket Cap
-4.21Reward/Risk
3.33%Risk Rate
TradingKey Stock Score of Evolus Inc
Currency: USD Updated: 2026-07-31Key Insights
Evolus Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 34 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.67.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evolus Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Evolus Inc Highlights
StrengthsRisks
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 47.05% year-on-year.
Fairly Valued
The company’s latest PE is -8.74, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.03M shares, decreasing 24.26% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 44.01K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
14.667
Target Price
+151.14%
Upside Space
Evolus Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
7
analysts
Buy
Current Rating
14.667
Target Price
+151.14%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Evolus Inc
EOLS
7
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
6.056
Sell
MA10
5.949
Sell
MA20
6.189
Sell
MA50
6.457
Sell
MA100
5.781
Buy
MA200
5.882
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Evolus Inc Info
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Ticker SymbolEOLS
CompanyEvolus Inc
CEOMoatazedi (David)
Websitehttps://www.evolus.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52778.700
+400.700 (+0.77%)
28516.700
+355.800 (+1.26%)
7535.200
+60.100 (+0.80%)
14586.000
-163.000 (-1.10%)
63643.000
+791.000 (+1.26%)
6406.400
+41.000 (+0.64%)
78.712
-7.222 (-8.40%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4065.670
+24.240 (+0.60%)
FAQs
What is the current price of Evolus Inc (EOLS)?
The current price of Evolus Inc (EOLS) is 5.84.
What is the symbol of Evolus Inc?
The ticker symbol of Evolus Inc is EOLS.
What is the 52-week high of Evolus Inc?
The 52-week high of Evolus Inc is 10.62.
What is the 52-week low of Evolus Inc?
The 52-week low of Evolus Inc is 3.86.
What is the market capitalization of Evolus Inc?
The market capitalization of Evolus Inc is 384.59M.
Is Evolus Inc (EOLS) currently rated as Buy, Hold, or Sell?
According to analysts, Evolus Inc (EOLS) has an overall rating of Buy, with a price target of 14.67.
What is the Earnings Per Share (EPS TTM) of Evolus Inc (EOLS)?
The Earnings Per Share (EPS TTM) of Evolus Inc (EOLS) is -0.80.